STOCKHOLM – August 3, 2026. Umecrine Cognition today announced that the last subject has been enrolled in the company’s ongoing Phase 1b/2a clinical study evaluating the safety, pharmacokinetics,…
STOCKHOLM – June 23, 2026. Umecrine Cognition today announced that it has completed an interim sample size analysis in its phase 1b/2a clinical study of golexanolone. The analysis concludes that…
STOCKHOLM – June 8 2026. Umecrine Cognition today announced that the company has resolved a directed share issue amounting to SEK 64 million, before transaction costs, in order to finalize its…
STOCKHOLM – May 27, 2026. Umecrine Cognition today announced new patient survey data confirming that central fatigue, characterized by a loss of self-motivation and cognitive involvement, is the…
STOCKHOLM – May 13, 2026. Umecrine Cognition today announced new data from the UK-PBC national cohort, to be presented at the EASL Congress 2026 in Barcelona. The data show that most patients with…
The shareholders in Umecrine Cognition AB, reg. no. 556698- 3655, are hereby given notice to attend the annual general shareholders’ meeting at 8:30 a.m. on Thursday 26 May 2026 at the company’s…